A Phase II Trial of Safety, Tolerability and Efficacy Study of Topical AKP-11 Administration to Participants with Arthritis.

This study tests a new topical (applied to the skin) medication called AKP-11 for people with arthritis — including osteoarthritis, gout, and rheumatoid arthritis. AKP-11 works differently from standard anti-inflammatory creams; it targets a pathway in the immune system called S1P1. Part A of the study tests two doses over 7 days in people with osteoarthritis. Part B tests the selected dose over 21 days in people with any form of inflammatory arthritis. The aim is to see whether AKP-11 is safe, tolerable, and able to reduce pain and swelling. You may be eligible if: - You are between 18 and 75 years old - You have arthritis (osteoarthritis in Part A; or gout, osteoarthritis, or rheumatoid arthritis in Part B) - Your pain level is at least 4 out of 10 - Your condition has been stable for at least 2 weeks - You are willing to use contraception during the study if you are of childbearing potential You may NOT be eligible if: - You are allergic to any ingredient in the study cream - You are currently taking immunosuppressant drugs or systemic steroids - You have an active cancer or a major immune disease (other than rheumatoid arthritis) - You have recently had joint surgery - You are pregnant or planning to become pregnant Talk to your doctor about whether this trial might be right for you.